SCHEMBL4353969

SCHEMBL4353969

Oc1c(Cl)cccc1NCC1=NCN=C1c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
ALOX12 P18054 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
FABP4 P15090 4/20 0.33
KDM4E B2RXH2 1/20 0.33
ADRA2A P08913 1/20 0.33
MAOA P21397 1/20 0.33
ADRA1D P25100 1/20 0.33
MAOB P27338 1/20 0.33
ADRA1A P35348 1/20 0.33
FABP3 P05413 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
FABP5 Q01469 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4349066 0.85 KDM4E (0.34) ADRA2BADRA2CALOX12MEN1KMT2A
SCHEMBL4342000 0.81 GSK3B (0.38) ALOX12MEN1KMT2AKDM4EMAOB
SCHEMBL4346821 0.79 ALOX5 (0.39) ADRA2BADRA2CALOX12MEN1KMT2A
SCHEMBL4351441 0.74 RPS6KA3 (0.36) MEN1KMT2AKDM4EMAOBNPC1
SCHEMBL112756 0.73 HSD17B10 (0.50) ALOX12MEN1KMT2AKDM4ERAB9A
SCHEMBL4357407 0.68 FFAR1 (0.37) MEN1KMT2AMAOBRAB9AMAPT
SCHEMBL4351936 0.64 ALOX12 (0.55) ALOX12MEN1KMT2AKDM4ELMNA
SCHEMBL4351156 0.64 SMN1; SMN2 (0.43) ALOX12MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL8446926 0.64 IDO1 (0.43) ALOX12MEN1KMT2AFABP4KDM4E
SCHEMBL4341643 0.63 RXFP1 (0.49) MEN1KMT2AKDM4ESMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 ADRA2B 599/4885ADRA2C 562/4885ALOX12 1546/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 ADRA2B 505/4885ADRA2C 558/4885ALOX12 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.